Disclosure statement
Dr. Schiller reports grants or contracts for clinical trials from AbbVie, Actininium, Actuate, Arog, Astellas, BMS/Celgene, Celator, Constellation, Daliichi-Sankyo, Deciphera, Delta-Fly, Forma, Fujifilm, Gamida, Genentech-Roche, Geron, Incyte, Karyopharm, Kite/Gilead, Mateon, Onconova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Sellas, Stemline, Takeda, Agios, Amgen, Jazz, Elevate, Bio, Ono-UK, Novartis, Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, Jazz, Stemline, kite, BMS, Sanofi, Astellas; leadership or fiduciary in other board, society, committee or advocacy group, paid or unpaid from ASH foundation Chair-unpaid; stock or stock options BMS, Amgen, Johnson & Johnson. Dr. Pasquini reports research support from Novartis, Kite, BMS, Amgen (completed 2019), Consultancy (listed as the professional providing insight), BMS (CAR T cell Steering Committee – former as of June 2021). Dr. Chhabra reports institutional research funding from Amgen, Janssen and Sanofi; and honoraria (for advisory boards) from GSK and Sanofi.
Data availability statement
CIBMTR supports accessibility of research in accord with the National Institutes of Health (NIH) Data Sharing Policy and the National Cancer Institute (NCI) Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR only releases de-identified datasets that comply with all relevant global regulations regarding privacy and confidentiality.